Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

485.16 -0.37 (-0.08%)
Streaming Delayed Price Updated: 12:53 PM EDT, Jun 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vertex Pharmaceuticals

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
43 44 Next >
Akero Therapeutics Stock Joins Elite Club Of Stocks With RS Ratings Over 90
Akero Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 73 to 99. 
Via Investor's Business Daily
Biotech Stocks Stand to Benefit as Biden Announces Support for Industry
President Biden has announced a new initiative to help U.S. biotech producers grow. Here's what this news means for biotech stocks. 
Via InvestorPlace
Sage Therapeutics Stock Scores Relative Strength Rating Upgrade
On Friday, Sage Therapeutics stock received a positive adjustment to its Relative Strength (RS) Rating, from 86 to 91. 
Via Investor's Business Daily
Amylyx Pharmaceuticals Stock Sees Relative Strength Rating Rise To 98
Amylyx Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating improve to 98, up from 83 the day before. 
Via Investor's Business Daily
Neurocrine Leads 5 Stocks To Watch In Sickly Market
Neurocrine Biosciences leads five medical stocks showing resilience. 
Via Investor's Business Daily
Vertex Pharma's Flagship Cystic Fibrosis Drug Scores FDA Approval For Infants
Via Benzinga
Where Vertex Pharmaceuticals Stands With Analysts
Vertex Pharmaceuticals (NASDAQ:VRTX) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Agios Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
Agios Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an increase from 65 to 93. 
Via Investor's Business Daily
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 6.64% on an annualized basis producing an average annual return of 17.25%. Currently, Vertex Pharmaceuticals... 
Via Benzinga
Legend Biotech Stock Joins Elite Club Of Stocks With RS Ratings Over 90
On Thursday, Legend Biotech stock had its Relative Strength (RS) Rating upgraded to 91, up from 87 a day earlier. 
Via Investor's Business Daily
Obesity And Back Pain: BioRestorative Therapies Inc. Is Working To Address 2 Common Ailments That Plague Americans with a Major Near Term Data Catalyst
By Paul Henley, Benzinga 
Via News Direct
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. 
Via Benzinga
Obesity And Back Pain: BioRestorative Therapies Inc. Is Working To Address 2 Common Ailments That Plague Americans with a Major Near Term Data Catalyst
In 2016, Americans spent roughly $380 billion on lower back and neck pain. In the same year, medical costs for adult obesity in the United States were $260.6 billion. 
Via Benzinga
Intercept Pharmaceutical Stock Shows Market Leadership; Earns 92 RS Rating
On Tuesday, Intercept Pharmaceutical stock had its Relative Strength Rating upgraded to 92, up from 89 a day earlier. 
Via Investor's Business Daily
5 Top Stocks Cathie Wood Is Selling This Week
Cathie Wood and her flagship ETF ARKK received $54.2 million of inflows earlier this month. Here's what she's selling. 
Via InvestorPlace
Relay Therapeutics Stock Shows Market Leadership With Jump To 94 RS Rating
Relay Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 84 to 94. 
Via Investor's Business Daily
Kymera Therapeutics Stock Scores Rising Relative Price Strength
Kymera Therapeutics stock hit a key performance benchmark, with its Relative Strength Rating upgradedjulie mak to 94. 
Via Investor's Business Daily
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $13,000 Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 6.35% on an annualized basis producing an average annual return of 14.14%. Currently, Vertex Pharmaceuticals... 
Via Benzinga
Devon Energy, Eli Lilly Are CNBC 'Fast Money' Mentions, With Kevin O'Leary Selling These 7 Stocks
CNBC’s "Fast Money: Halftime Report" delivers market-moving news to investors. 
Via Benzinga
This Analyst Boosts Price Target On Home Depot Following Strong Earnings, Plus Citigroup Slashes PT On This Stock By Over 60%
Baird boosted the price target for The Home Depot, Inc. (NYSE: HD) from $335 to $360. Home Depot shares fell 0.2% to $326.58 in pre-market trading. 
Via Benzinga
3 Best Funds for Aggressive Investors
These are the three best funds for aggressive investors. ETFs like BUG, RYT, and BBH can make great investments in the rest of the year. 
Via InvestorPlace
Rocket Pharmaceuticals Stock Scores Rising Relative Strength Upgrade
On Thursday, Rocket Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 88 to 94. 
Via Investor's Business Daily
Acadia Terminates Painkiller, Cancer Candidate After Disappointing Data
Via Benzinga
Peering Into Vertex Pharmaceuticals Recent Short Interest
Vertex Pharmaceuticals' (NASDAQ:VRTX) short percent of float has risen 13.71% since its last report. The company recently reported that it has 3.59 million shares... 
Via Benzinga
Vertex Makes Bullish Move On Earnings, Leading 5 Stocks To Watch
Vertex Pharmaceuticals headlines five stocks to watch this week. 
Via Investor's Business Daily
Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion
Shares of Pfizer's rumored takeover target have rocketed for two days running. 
Via Investor's Business Daily
Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review
The Nasdaq and small caps rose while the S&P 500 is hitting resistance. 
Via Investor's Business Daily
$1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 7.01% on an annualized basis producing an average annual return of 18.39%. Currently, Vertex Pharmaceuticals... 
Via Benzinga
Vertex Pharmaceuticals: Q2 Earnings Insights
Vertex Pharmaceuticals (NASDAQ:VRTX) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
43 44 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.